TBPH(TBPH)
TBPH
ANALYST COVERAGE15 analysts
HOLD
▲ +66.5%upside to target
L $14.00
Med $27.00consensus
H $40.00PRICE
Prev Close
16.51
Open
16.49
Day Range16.21 – 16.59
16.21
16.59
52W Range9.07 – 21.03
9.07
21.03
60% of range
VOLUME & SIZE
Avg Volume
611.1K
FUNDAMENTALS
P/E Ratio
7.3x
Value territory
EPS (TTM)
—
Div Yield
No dividend
Beta
0.69
Low vol
TECHNICAL
RSI (14)
41
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 19
DEx-Dividend
In 88 days
Aug 14
PDividend Pay
In 105 days
Aug 31
Key MetricsTTM
Market Cap$836.19M
Revenue TTM$109.78M
Net Income TTM$114.54M
Free Cash Flow$268.74M
Gross Margin80.4%
Operating Margin0.1%
Net Margin104.3%
Return on Equity43.8%
Return on Assets24.3%
Debt / Equity0.25
Current Ratio13.14
EPS TTM$2.23
TBPH News
About
theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CEO
Rick Winningham
Country
Cayman Islands
Aine MillerSenior Vice President of Development & Head of Ireland Office
Aziz SawafSenior Vice President & Chief Financial Officer
Brett A. GrimaudSenior Vice President, General Counsel & Secretary
Rick E. WinninghamChief Executive Officer & Director
Stuart KnightSenior Vice President of IT&I and Chief Information Officer
Rhonda F. FarnumChief Business Officer and Senior Vice President of Commercial & Medical Affairs
Stacy L. PryceSenior Vice President & Chief Strategy Officer